Compound ID | 1804

Update compound information

ASN-4

Synonym(s): ASN200 program

Class: null

Agent Type: Indirect acting;
Spectrum of activity: Gram-negative
Mechanism of action: Shows anti-inflammatory effects
Target Pathogen: Active against Escherichia coli
Description: Humanized monoclonal antibody
Institute where first reported: BB100, LLC (subsidiary of Bravos Biosciences), Arsanis
Year first mentioned: 2018
Development status: Experimental
External links:
Citations:
  • https://carb-x.org/carb-x-news/carb-x-funds-bb100-to-develop-a-unique-monoclonal-antibody-to-prevent-and-treat-hyper-virulent-multi-drug-resistant-e-coli-infections/
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021686/
  • https://www.life-sciences-europe.com/product/asn-mab-bravos-bioscience-bb100-llc-biosciences-group-2001-29396.html

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.